GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedPacto Inc (XKRX:235980) » Definitions » Loans Receivable

MedPacto (XKRX:235980) Loans Receivable : ₩0.00 Mil (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is MedPacto Loans Receivable?

MedPacto's Loans Receivable for the quarter that ended in Dec. 2024 was ₩0.00 Mil.


MedPacto Loans Receivable Historical Data

The historical data trend for MedPacto's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedPacto Loans Receivable Chart

MedPacto Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial - - - - -

MedPacto Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

MedPacto Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


MedPacto Loans Receivable Related Terms

Thank you for viewing the detailed overview of MedPacto's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


MedPacto Business Description

Traded in Other Exchanges
N/A
Address
92 Myeongdal -ro, Seocho-gu, Borim Building, Seoul, KOR
MedPacto Inc is a drug discovery and development company based in South Korea. It is engaged in developing anticancer drugs and medicines which focuses on therapeutics targeting cancer and autoimmune diseases. Its products are in pipeline.

MedPacto Headlines

No Headlines